Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab
The Journal of Infectious Diseases · 11.07.2025 · 231 (6) · 1440-1444
DOI: 10.1093/infdis/jiaf159 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 03.04.2025. Verfasst von Joseph J Eron und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, Antibodies, Monoclonal, Humanized, Antibodies, Neutralizing, Broadly Neutralizing Antibodies. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Gilead Sciences, Inc.
Abstract (Originalsprache)
Background
The combination of 2 broadly neutralizing antibodies (bNAbs), teropavimab and zinlirvimab, plus the capsid inhibitor lenacapavir, is a potential twice-yearly regimen for HIV-1 treatment. The level of bNAb susceptibility to maintain virologic suppression is unknown; therefore, we evaluated this combination in participants meeting stringent viral sensitivity criteria to only 1 of the 2 bNAbs.
Methods
This was a pilot study within a proof-of-concept phase 1b study.
Results
No serious treatment-emergent adverse events occurred and 8 of 10 participants remained virologically suppressed at week 26.
Conclusions
More inclusive bNAb susceptibility criteria may be appropriate for future studies of this combination treatment. Clinical Trials Registration. NCT04811040.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.
- Division of Infectious Diseases, East Carolina University, Greenville, North Carolina, USA.
- Cinical Research, Gilead Sciences, Inc, Foster City, California, USA.
- Biostatistics, Gilead Sciences, Inc, Foster City, California, USA.
- Laboratory of Molecular Immunology, Rockefeller University, New York, New York, USA.
- Crofoot MD Clinic and Research Center, Houston, Texas, USA.
ORCID-Profile: Joseph J Eron, Megha L Mehrotra, Marina Caskey, Yanan Zheng
Förderung
- Gilead Sciences, Inc
Zitieren
APA
Eron, J. J., Cook, P. P., Mehrotra, M. L., Huang, H., Caskey, M., Crofoot, G. E., Gorgos, L., VanderVeen, L. A., Zheng, Y., Collins, S. E., Osiyemi, O. O., Brinson, C., & DeJesus, E. (2025). Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab. The Journal of Infectious Diseases, 231(6), 1440-1444. https://doi.org/10.1093/infdis/jiaf159
Vancouver
Eron JJ, Cook PP, Mehrotra ML, Huang H, Caskey M, Crofoot GE, et al. Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab. The Journal of Infectious Diseases. 2025;231(6):1440-1444. doi:10.1093/infdis/jiaf159
BibTeX
@article{Eron2025,
author = {Eron, Joseph J and Cook, Paul P and Mehrotra, Megha L and Huang, Hailin and Caskey, Marina and Crofoot, Gordon E and Gorgos, Linda and VanderVeen, Laurie A and Zheng, Yanan and Collins, Sean E and Osiyemi, Olayemi O and Brinson, Cynthia and DeJesus, Edwin},
title = {Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab},
journal = {The Journal of Infectious Diseases},
year = {2025},
volume = {231},
number = {6},
pages = {1440--1444},
doi = {10.1093/infdis/jiaf159}
}
EUVIMED